BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses

Autor:	Irit Avivi, Efrat Luttwak, Esther Saiag, Tami Halperin, Shira Haberman, Ariel Sarig, Sivan Levi, Anat Aharon, Yair Herishanu, Chava Perry
Rok vydání:	2022
Předmět:	Vaccines COVID-19 Vaccines SARS-CoV-2 Seroconversion Lymphoma Non-Hodgkin Immunization Secondary COVID-19 Humans Prospective Studies RNA Messenger Hematology BNT162 Vaccine
Zdroj:	British Journal of Haematology. 196:1329-1333
ISSN:	1365-2141 0007-1048
Popis:	This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine booster in 44 B-cell non-Hodgkin lymphoma (B-NHL) patients who failed to respond to two prior doses [42 previously exposed to anti-CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients. Longer time from last anti-CD20 moAb (6 months) and diagnosis of aggressive lymphoma compared to other, incurable B-NHLs were associated with increased seroconversion rates (47.8% vs.10.5%, p = 0.019 and 50% vs. 17.9%, p = 0.025 respectively). Thus, seronegative patients with B-NHL that completed anti-CD20 therapy more than 6 months prior to the booster have greater chances to achieve seroconversion.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af60e79e7e914701b622c9fb1ac277a9 https://doi.org/10.1111/bjh.18029 Zobrazit plný text záznamu Plný text